How big is Akoya Biosciences, Inc.?

As of Jun 18, Akoya Biosciences, Inc. has a market capitalization of 62.44 million, with net sales of 79.95 million and a net profit of -47.53 million over the last four quarters. Shareholder's funds are 7.59 million, and total assets are 125.00 million.

As of Jun 18, Akoya Biosciences, Inc. has a market capitalization of 62.44 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 79.95 million, while the sum of net profit for the same period is -47.53 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 7.59 million, and total assets amount to 125.00 million.

What does Akoya Biosciences, Inc. do?

Akoya Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $17 million and a net loss of $16 million as of March 2025. The company has a market cap of $62.44 million and does not pay dividends.

Overview:<BR>Akoya Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 17 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -16 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 62.44 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -8.86 <BR>Return on Equity: 787.71% <BR>Price to Book: -10.60 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Akoya Biosciences, Inc.?

Is Akoya Biosciences, Inc. overvalued or undervalued?

As of November 8, 2021, Akoya Biosciences, Inc. is considered risky due to negative valuation ratios, including a Price to Book Value of -9.82 and an EV to EBITDA of -3.70, alongside a troubling -80.86% ROCE, which highlights its overvaluation and poor performance compared to peers and the S&P 500.

As of 8 November 2021, the valuation grade for Akoya Biosciences, Inc. has moved from does not qualify to risky, indicating heightened concerns regarding its financial health. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -9.82 and an EV to EBITDA of -3.70. Additionally, the Return on Capital Employed (ROCE) stands at a troubling -80.86%, reflecting significant inefficiencies in generating returns from its capital.<BR><BR>In comparison to its peers, Akoya's valuation ratios are less favorable; for instance, MeiraGTx Holdings Plc has an EV to EBITDA of -4.4399, while Monte Rosa Therapeutics, Inc. boasts a much more attractive P/E ratio of 12.2660. The stock has underperformed against the S&P 500, with a year-to-date return of -43.67% compared to the index's 12.22%, reinforcing the notion of its overvaluation in the current market context.

Is Akoya Biosciences, Inc. technically bullish or bearish?

As of June 27, 2025, Akoya Biosciences, Inc. is in a mildly bearish trend, indicated by bearish daily moving averages and Bollinger Bands, despite mixed signals from the MACD and RSI.

As of 27 June 2025, the technical trend for Akoya Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend and monthly Bollinger Bands also showing bearish signals. While the MACD is mildly bullish on both weekly and monthly time frames, the overall indicators suggest weakness. The RSI shows a bullish signal on the monthly but no signal on the weekly, indicating mixed momentum. Additionally, Dow Theory indicates a bearish trend on the monthly. There is no available return data to compare the company's performance against the S&P 500.